Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor
详细信息 查看全文
- 作者：Professor R. Preston Mason (1) (2)
- 刊名：Drugs
- 出版年：2008
- 出版时间：May 2008
- 年：2008
- 卷：68
- 期：7
- 页码：885-900
- 全文大小：153KB
- 参考文献：1. Yach D, Hawkes C, Gould CL, et al. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004; 291(21): 2616鈥?2 CrossRef
2. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 2002; 15(11): 28鈥?6
3. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 2002; 25(3): 482鈥? CrossRef
4. Beaglehole R, editor. The world health report: 2003. Shaping the future. Geneva: WHO, 2003
5. Murray CJL, Lopez AD. The global burden of disease. Boston (MA): Harvard School of Public Health, 1996
6. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303(6797): 276鈥?2 CrossRef
7. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual鈥檚 absolute cardiovascular risk. Lancet 2005; 365(9457): 434鈥?1
8. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992; 86(3): 1046鈥?0 CrossRef
9. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16(2): 434鈥?4 CrossRef
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7鈥?2 CrossRef
11. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363(9411): 757鈥?7 CrossRef
12. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227鈥?9 CrossRef
13. Williams B, Wilson K, Lacey L, et al. The prevalence and management of patients with co-existing hypertension and hypercholesterolaemia in the UK. European Society of Cardiology 2004 congress; 2004 Aug 28鈥揝ep 1; Munich
14. Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004; 10(12): 926鈥?2
15. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss 2004; 97(10): 1019鈥?0
16. European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011鈥?3 CrossRef
17. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143鈥?21
18. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484鈥?1 CrossRef
19. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293鈥? CrossRef
20. The University of Edinburgh. Cardiovascular risk calculator [online]. Available from URL: http://cvrisk.mvm.ed.ac.uk/calculator/framingham.htm [Accessed 2008 Mar 25]
21. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109 (23 Suppl. 1): III27鈥?2
22. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20 (11 Suppl. 2): II鈥?鈥?0
23. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81(2): 491鈥? CrossRef
24. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23(2): 233鈥?6
25. Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med 2005; 118 Suppl. 12A: 54鈥?1 CrossRef
26. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105(17): 2107鈥?1 CrossRef
27. Vergnani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and Superoxide production: key role of L-arginine availability. Circulation 2000; 101(11): 1261鈥? CrossRef
28. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223鈥?1 CrossRef
29. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109 (21 Suppl. 1): II34鈥?1
30. Quyyumi AA, Mulcahy D, Andrews NP, et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia: comparison of acetylcholine and substance P. Circulation 1997; 95(1): 104鈥?0 CrossRef
31. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23(12): 2155鈥?3 CrossRef
32. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97(6): 576鈥?0 CrossRef
33. Zhang X, Kichuk MR, Mitai S, et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol 1999; 84(4A): 27鈥?3L CrossRef
34. Mason RP, Campbell SF, Wang SD, et al. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 1989; 36(4): 634鈥?0
35. Mason RP, Moisey DM, Shajenko L. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 1992; 41(2): 315鈥?1
36. Kuryata OV, Yegorova YV. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kardiol Pol 2006; 64(1): 44鈥?
37. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88(11): 1306鈥? CrossRef
38. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholester-olemic women. J Cardiovasc Pharmacol 2000; 36(5): 617鈥?1 CrossRef
39. Mercuro G, Zoncu S, Saiu F, et al. Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. Am J Cardiol 2002; 90(7): 747鈥?0 CrossRef
40. Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36(2): 410鈥? CrossRef
41. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87(2): 563鈥? CrossRef
42. Wassmann S, Ribaudo N, Faul A, et al. Effect of atorvastatin 80mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl. Am J Cardiol 2004; 93(1): 84鈥? CrossRef
43. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103(1): 113鈥? CrossRef
44. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108(4): 426鈥?1 CrossRef
45. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105(6): 691鈥? CrossRef
46. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107(13): 1750鈥? CrossRef
47. Manfrini O, Pizzi C, Morgagni G, et al. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol 2004; 93(11): 1391鈥?30 CrossRef
48. Walter DH, Fichtischerer S, Britten MB, et al. Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002; 89(1): 1鈥? CrossRef
49. Iwakura K, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27(5): 534鈥? CrossRef
50. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004; 95(2): 217鈥?3 CrossRef
51. Mason RP, Jacob RF, Kay RD, et al. Synergistic stimulation of nitric oxide release from human endothelial cells with amlodipine and atorvastatin [abstract]. Eur Heart J 2003; 24: 214A CrossRef
52. van de Poll SW, Delsing DJ, Jukema JW, et al. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002; 164(1): 65鈥?1 CrossRef
53. Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 2003; 42(1): 63鈥?0 CrossRef
54. Jeng JR, Sheu WH, Jeng CY, et al. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996; 9(5): 484鈥?0 CrossRef
55. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79(1): 84鈥? CrossRef
56. Seljeflot I, Tonstad S, Hjermann I, et al. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002; 105(4): 285鈥?0 CrossRef
57. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005; 91(1): 27鈥?1 CrossRef
58. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipineatorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004; 17(9): 823鈥? CrossRef
59. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens Suppl 1999; 17(5): S41鈥?
60. Leibovitz E, Beniashvili M, Zimlichman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 2003; 16 (9 Pt 1): 715鈥? au61._Cohn JN, Neutel J, Houston M, et al. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia: the Avalon Arterial Wall Compliance (AWC) trial [abstract no. LB3]. American Society of Hypertension 20th Scientific Meeting; 2005 May 14鈥?8; San Francisco (CA) CrossRef
61. Cohn JN, Neutel J, Houston M, et al. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia: the Avalon Arterial Wall Compliance (AWC) trial [abstract no. LB3]. American Society of Hypertension 20th Scientific Meeting; 2005 May 14-18; San Francisco (CA)
62. ALLHAT investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981鈥?7 CrossRef
63. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022鈥?1 CrossRef
64. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study. A randomized controlled trial. JAMA 2004; 292(18): 2217鈥?5
65. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495鈥?04 CrossRef
66. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685鈥?6 CrossRef
67. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291(9): 1071鈥?0 CrossRef
68. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149鈥?8 CrossRef
69. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001; 19(6): 1139鈥?7 CrossRef
70. Sever PS. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? Am J Med 2005; 118 Suppl. 12A: 3鈥? CrossRef
71. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27(24): 2982鈥? CrossRef
72. Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract 2005; 59(7): 839鈥?6 CrossRef
73. Pedrinelli R, Esposti ED, Dell鈥橭mo G. LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis 2005; 180(1): 137鈥?3 CrossRef
74. Flack JM, Houston M, Neutel J, et al. Efficacy and safety of atorvastatin plus amlodipine versus either agent alone in patients with concomitant dyslipidaemia and hypertension: the AVALON study [abstract]. J Hypertens 2004; 22 Suppl. 1: 12S
75. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens (Greenwich) 2005; 7(5): 264鈥?3 CrossRef
76. Dorval JF, Anderson T, Buithieu J, et al. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Am J Cardiol 2005; 95(2): 249鈥?3 CrossRef
77. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmaco-dynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J Clin Pharmacol 2007; 47(12): 1555鈥?9 CrossRef
78. Preston RA, Harvey P, Herfert O, et al. Reduction in Framingham cardiovascular risk with concomitant treatment of hypertension/dyslipidaemia with amlodipine/atorvastatin [poster]. Am J Hypertens 2005; 18 (5 Pt 2): 226鈥?A CrossRef
79. Pfizer. Caduet庐 (amlodipine besylate/atorvastatin calcium) tablets: product information [online]. Available from URL: http://www.pfizer.com/files/products/uspi_caduet.pdf [Accessed 2008 March 19]
80. Chung M, Randinitis E, Calcagni A, et al. Bioavailability of dual therapy: a fixed-dose combination tablet of amlodipine and atorvastatin [abstract]. XIIIth International Symposium on Atherosclerosis; 2003 Sep 28鈥揙ct 2; Kyoto, 4
81. Pfizer. Amlodipine product information [online]. Available from URL: http://www.norvasc.com/professional [Accessed 2008 Mar 6]
82. Pfizer. Lipitor庐 (atorvastatin calcium) tablets [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_lipitor.pdf. [Accessed 2008 Mar 6]
83. Chung M, Randinitis E, Calcagni A, et al. Effect of food on the bioavailability of dual therapy: a fixed-dose combination tablet of amlodipine and atorvastatin [abstract]. Xlllth International Symposium on Atherosclerosis; 2003 Sep 28-Oct 2; Kyoto, 174
84. Anon. Amlodipine/atorvastatin (Caduet) [letter]. Med Lett Drugs Ther 2004; 46(1186): 56
85. Preston RA, Sun F, Tarasenko L. Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidaemia in the Respond study [poster]. Am J Hypertens 2005; 18 (5 Pt II): 92鈥?A CrossRef
86. Akosah KO, Gower E, Groon L, et al. Mild hypercholesterolemia and premature heart disease: do the national criteria underestimate disease risk? J Am Coll Cardiol 2000; 35(5): 1178鈥?4 CrossRef
87. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147鈥?2 CrossRef
88. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): 2鈥? - 作者单位：Professor R. Preston Mason (1) (2)
1. Department of Medicine, Brigham and Women鈥檚 Hospital, Boston, Massachusetts, USA
2. Elucida Research LLC, Beverly, Massachusetts, USA
文摘
Cardiovascular disease is the leading cause of morbidity and mortality throughout the developed world. Risk factors for cardiovascular disease commonly coexist, which multiplies the overall or absolute risk of clinical events. Furthermore, evidence from observational and intervention trials suggest that the numerical risk associated with factors such as cholesterol level and blood pressure increases continuously. These findings concur with results from large-scale clinical trials showing that clinical benefits can be achieved with lowering cholesterol levels, irrespective of the initial levels. Cardiovascular risk factors have been shown to adversely influence vascular endothelial function. In particular, reduced bioavailability of endothelial-dependent nitric oxide production as a result of enhanced oxidative stress represents a common pathological mechanism of cardiovascular risk factors. This contributes to the observation that risk factors increase the overall risk of clinical events in an apparent additive fashion. Treatment guidelines now reflect these advances in our knowledge of risk factors by encouraging approaches that aim to reduce absolute risk, rather than addressing single risk factors in isolation. In response to this, a single pill combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor (statin) has emerged as a means of addressing the suboptimal rates of goal attainment for concomitant hypertension and dyslipidaemia. Moreover, it can be viewed as a new therapeutic approach that seeks to comprehensively manage risk factors and enhance cardiovascular protection for patients at risk. Both experimental and clinical studies indicate that this approach is effective for reducing both the pathophysiological markers of atherosclerotic disease and its clinical consequences. This article provides an overview of the evidence for this new approach and recommends applications for use in clinical settings.